ET Intelligence Group: Symbiotec Pharmalab plans to raise ₹150 crore through a fresh issue to repay debt and ₹1,607 crore through an offer for sale.
The promoter group’s stake will fall to 33.3% after the IPO from 36.4%. The company is engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products.
Over two-third of the revenue comes from international markets with Europe contributing nearly 30%. Top five products contribute nearly 63% to revenue, signalling product concentration. The valuation is attractive compared with peers. Given these factors and market leadership in some of the products, investors with high-risk appetite may apply for the long-term.
Business
Incorporated in 2002, Symbiotec Pharmalab has a global leadership position in corticosteroid and steroidal-hormone APIs in volume terms in FY26, with a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs According to Frost & Sullivan. I
t was the only company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in FY26. The company has a backward-integrated platform with approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations. APIs continue to be the primary revenue driver.
Leave a Reply